You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

neuroendocrine prostate carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor Trial (ESK981)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • +6 more
  • (no location specified)
Aug 4, 2023

Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma Trial in Boston

Not yet recruiting
  • Advanced Prostate Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Sep 25, 2023

Metastatic Malignant Tumor in the Viscera, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic

Not yet recruiting
  • Metastatic Malignant Neoplasm in the Viscera
  • +4 more
  • Lutetium Lu 177 Dotatate
  • (no location specified)
Jan 25, 2023

Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC) Trial (PT217)

Not yet recruiting
  • Small Cell Lung Cancer (SCLC)
  • +3 more
  • (no location specified)
Dec 7, 2022

Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +7 more
  • Biopsy
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma Trial in San Francisco (Apalutamide, Cetrelimab)

Recruiting
  • Small Cell Neuroendocrine Carcinoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Mar 21, 2022

Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)

Not yet recruiting
  • Anal Squamous Cell Carcinoma
  • +7 more
  • Regorafenib in combination with Tislelizumab
  • (no location specified)
Oct 12, 2022

Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Metastatic Prostate Carcinoma Trial in Seattle

Active, not recruiting
  • Castration-Sensitive Prostate Carcinoma
  • +7 more
  • Antiandrogen Therapy
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 8, 2022

Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma

Recruiting
  • Bladder Small Cell Neuroendocrine Carcinoma
  • +16 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 23, 2022

Advanced Malignant Solid Tumor, Anal Carcinoma, Biliary Tract Carcinoma Trial in Jacksonville (Clinical Encounter, Home Health

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +18 more
  • Clinical Encounter
  • +3 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Jul 24, 2023

Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder Trial in United States (Ipilimumab, Nivolumab)

Recruiting
  • Genitourinary Cancer
  • +7 more
  • La Jolla, California
  • +5 more
Jul 5, 2022

Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Houston

Recruiting
  • Aggressive Variant Prostate Carcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 10, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7 Trial in Atlanta (CT

Active, not recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • CT (Computed Tomography)
  • +2 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Mar 3, 2022

Medullary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroid Carcinoma, Medullary Trial in Groningen (18F-PSMA-1007)

Not yet recruiting
  • Medullary Thyroid Cancer
  • +3 more
  • Groningen, Netherlands
    University Medical Centre Groningen
Sep 8, 2022

Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer Trial in Omaha

Recruiting
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • +6 more
  • Omaha, Nebraska
    Urology Cancer Center/XCancer
Nov 29, 2022

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate

Suspended
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Abiraterone Acetate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 27, 2022

Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))

Recruiting
  • Gastrointestinal Neuroendocrine Carcinoma
  • Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 1, 2023

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

Tumor Recurrence Following Radiotherapy

Recruiting
  • Prostate Cancer
    • Rochester, Minnesota
      Mayo Clinic
    Jan 20, 2023

    Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Zhengzhou (ZG006)

    Not yet recruiting
    • Small Cell Lung Cancer
    • Neuroendocrine Carcinoma
    • ZG006
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Aug 6, 2023

    Large Cell Neuroendocrine Carcinoma of the Lung Trial in Athens (Atezolizumab, Carboplatin, Etoposide)

    Completed
    • Large Cell Neuroendocrine Carcinoma of the Lung
    • Athens, Greece
    • +1 more
    Sep 16, 2023

    Surufatinib Plus Sintilimab Combined With Chemotherapy in

    Recruiting
    • Gastric Neuroendocrine Carcinoma
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Oct 22, 2023

    Neuroendocrine Carcinoma Trial in Wuhan (Surufatinib and Serplulimab)

    Not yet recruiting
    • Neuroendocrine Carcinoma
    • Surufatinib and Serplulimab
    • Wuhan, Hubei, China
      Cancer Center, Union Hospital, Tongji Medical College, Huazhong
    Feb 18, 2023

    Neuroendocrine Carcinoma of the Bladder, Bladder Cancer Trial (Adebrelimab, Etoposide, Cisplatin)

    Not yet recruiting
    • Neuroendocrine Carcinoma of the Bladder
    • Bladder Cancer
    • (no location specified)
    Oct 14, 2023